An assessment of the first 3 years' use of Implanon® in Luton. Issue 4 (1st October 2005)

• Record Type: Journal Article
• Authors: Agrawal, Anjali; Robinson, Christine
• Is Part Of: Journal of family planning and reproductive health care. Volume 31:Issue 4(2005)
• Page Start: 310
• Page End: 312
• Publication Date: 2005-10-01
• Subjects: Birth control -- Periodicals; Contraception -- Periodicals; Reproductive health -- Periodicals; 613.905
• DOI: 10.1783/147118905774480581
• Languages: English
• ISSNs: 1471-1893

Abstract

Abstract : Objectives: Implanon® was introduced in the UK in September 1999. We present here the results of our first 106 Implanon insertions, performed over a period of 18 months. The aims of the study were to study the clinical and demographic profile of Implanon users, to assess the continuation rates of Implanon in the local population, and to identify the reasons for removal. Methods: This was a case note-based study in which the data were transferred to a standardised pre-tested proforma. Results: The age range of the 106 Implanon users was 15–43 years. Eighty-six of these clients had their Implanon removed and the Implanon status of 20 clients is not known since they were lost to follow-up by our service. Of these 86 cases, 26 had completed the full 3-year period; therefore, the continuation rate at 3 years was 30.2%. The continuation rate at the end of 1 year was 69.8% and at 2 years was 44.1%. Of the 60 women who had their Implanon removed before the recommended 3-year period, the most common reason was for bleeding irregularity (24 cases, 40%). Conclusions: This is the first published study set in the UK within a real-life setting to follow up a cohort of Implanon users for the full 3-year period. No contraceptive failures were found, replicating previous clinical trials. The continuation rate in this real-life situation was quite low compared to clinical trials. This is frequently the case when comparing real-life situations with clinical trials and may be in part due to higher motivation on the part of clinical trial participants.